Association of differential censoring with survival and suboptimal control arms among oncology clinical trials
Eric J. Hsua b, Timothy A. Linc d e f, Dor Reuven Dabushg h, Zachary Ryan McCawi j, Alex Koongd f, Christine F. Lind f, Joseph Abi Jaouded f, Roshal R. Pateld f, Ramez Kouzyd f, Molly Blue El Alamd f, Sonal Suresh Noticewalad f, Yumeng Yang
Papers open inside SciRah from the original publisher or repository; SciRah never hosts them.
Abstract
Differential censoring, which refers to censoring imbalance between treatment arms, may bias the interpretation of survival outcomes in clinical trials. In 146 phase III oncology trials with statistically significant time-to-event surrogate primary endpoints, we evaluated the association between differential censoring in the surrogate primary endpoints, control arm adequacy, and the subsequent statistical significance of overall survival results. Twenty-four (16%) trials exhibited differential censoring that favored the control arm, whereas 15 (10%) exhibited differential censoring that favored the experimental arm. Positive overall survival was more common in control arm differential censoring trials (63%) than in trials without differential censoring (37%) or with experimental arm differential censoring (47%; odds ratio = 2.64, 95% confidence interval = 1.10 to 7.20; P = .04). Control arm differential censoring trials more frequently used suboptimal control arms at 46% compared with 20% without differential censoring and 13% with experimental arm differential censoring (odds ratio = 3.60, 95% confidence interval = 1.29 to 10.0; P = .007). The presence of control arm differential censoring in trials with surrogate primary endpoints, especially in those with overall survival conversion, may indicate an inadequate control arm and should be examined and explained.
TL;DRThe presence of ConDC in trials with surrogate PEPs, especially in those with OS conversion, may indicate an inadequate control arm and should be examined and explained. (Semantic Scholar)